Loading…
Loading…
See exactly how PWS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PWS and 80,000+ other tickers.
Pacer Funds Trust - Pacer WealthShield ETF is an exchange traded fund launched and managed by Pacer Advisors, Inc. The fund invests in public equity and fixed income markets of the United States. It invests directly and through other funds to create its portfolio. For its equity portion, the fund invests in stocks of companies operating across diversified sectors. It invests in stocks of large-cap companies. For its fixed income portion, the fund invests in U.S. Treasury securities and U.S. high yield corporate bond securities with varying maturities. It seeks to track the performance of the…
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadli
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 De
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadli
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. (âAardvarkâ
RENSSELAER, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. (“ConSynance”), a clinical-stage biotechnology company developing first-in-class therapies for neurobehavioral symptoms in rare neurodevelopmental disorders, today announced that the first participant has been dosed in its Phase 2a clinical trial of CSTI-500 for Prader-Willi syndrome (PWS), marking a significant clinical development milestone for the program.